↑ 疾患リストへ ← 戻る

 280. 巨大動静脈奇形(頚部顔面又は四肢病変) [臨床試験数:17,薬物数:17(DrugBank:10),標的遺伝子数:8,標的パスウェイ数:106] 

Searched query = "Huge arteriovenous malformation with cervicofacial or limb lesion", "Huge arteriovenous malformation", "Arteriovenous malformation"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR19000219012019-03-201 April 2019Efficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot StudyEfficacy and Safety of Thalidomide for the Treatment of Arteriovenous Malformations in Central Nervous System: Pilot Studycentral nervous system arteriovenous malformationsExperimental group:Oral thalidomide;Control group:conservative or surgical treatment;Xuanwu Hospital, Capital Medical UniversityRecruitingBothExperimental group:30;Control group:30;Phase 0China
2EUCTR2018-001359-11-FR22/02/201930 April 20190.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial0.1% topical sirolimus in the treatment of cutaneous microcystic lymphatic malformations in children and adults: phase II, split-body randomized, double-blind, vehicle-controlled clinical trial - TOPICALCutaneous microcystic lymphatic malformations (CMLM) in children and adults
MedDRA version: 20.0 Level: LLT Classification code 10003229 Term: Arteriovenous malformations System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
Product Name: Sirolimus 0,1% crème
Pharmaceutical Form: Cream
INN or Proposed INN: SIROLIMUS
CAS Number: 53123-88-9
Concentration unit: % (W/W) percent weight/weight
Concentration type: equal
Concentration number: 0.1-
Pharmaceutical form of the placebo: Cream
Route of administration of the placebo: Cutaneous use
CHRU TOURSAuthorised Female: yes
Male: yes
55Phase 2France
3ChiCTR18000176162018-08-0620 August 2018A randomized controlled trial for comparing the effect and outcomes with different embolic agent: Absolute ethanol, Onyx and n-BCA in the treatment of AVMA randomized controlled trial for comparing the effect and outcomes with different embolic agent: Absolute ethanol, Onyx and n-BCA in the treatment of AVMarteriovenous malformationsEthanol group:Embolization with ethanol;Onyx group:Embolization with Onyx;n-BCA group:Embolization with n-BCA;Shanghai 9th People's Hospital, Shanghai Jiaotong University School of MedicineRecruitingBothEthanol group:30;Onyx group:30;n-BCA group:30;New Treatment Measure Clinical StudyChina
4ChiCTR18000152202018-03-1430 April 2018Prospective evaluation of embolization with absolute alcohol in the treatment of arteriovenous malformationsProspective evaluation of embolization with absolute alcohol in the treatment of arteriovenous malformationsarteriovenous malformationsEthanol group:Embolization with absolute ethanol;Shanghai 9th People's Hospital, Shanghai Jiaotong University School of MedicineRecruitingBothEthanol group:30;New Treatment Measure Clinical StudyChina
5NCT02625389November 29, 201717 September 2018Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.Safety and Efficacy of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. A Phase IV Study.Congenital Hemangioma;Hemangioendothelioma;Angiosarcoma;Arteriovenous MalformationDrug: Lipiodol® Ultra Fluid with surgical gluesGuerbetRecruiting18 YearsN/AAll125Phase 4India
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6JPRN-UMIN0000305222017/11/142 April 2019A multicenter, single-arm, prospective study assessing efficacy and safety of the Sirolimus in the Treatment of intractable vascular anomaliesIntractable vascular anomalies: Cystic lymphatic malformation, Lymphangiomatosis (Generalized lymphatic anomaly, Kaposiform lymphangiomatosis), Gorham-Stout disease, Kaposiform hemangioendothelioma and Tuffted angioma with Kasabach-Merritt phenomenon, Nenous malformation, Arteriovenous malformation, Klippel-Trenaunay-Weber syndrome,Bluerubber bleb nevus syndrome, Complex-combined vascular malformationsBody surface area (BSA) >= 1.0m2: an initial dose of sirolimus (2mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.
BSA < 1.0m2: an initial dose of sirolimus (1mg/day) is single orally administered under fed or fasting condition. Subsequently, the sirolimus dosage is adjusted to achieve trough levels between 5-15 ng/mL. Maximum dose of sirolimus is 4 mg per day.
Gifu UniversityRecruitingNot applicableNot applicableMale and Female50Not selectedJapan
7NCT03306836September 201616 December 2017Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid Operation 2Multi-center,Single Blind,Prospective Randomized Controlled Trial of Exploration of Anticoagulation Program in Cerebral Aneurysm and Arteriovenous Malformations With Hybrid OperationCerebral Aneurysm;Arteriovenous MalformationsDrug: Heparin SodiumBeijing Tiantan HospitalTang-Du Hospital;Kunming Medical University;First Affiliated Hospital of Fujian Medical University;Nanjing PLA General Hospital;Fujian Medical University Union HospitalRecruitingN/A70 YearsAll408N/AChina
8NCT02314377June 201612 November 2018Bevacizumab Therapy for Brain Arteriovenous MalformationBevacizumab Therapy for Brain Arteriovenous MalformationBrain Arteriovenous MalformationDrug: BevacizumabUniversity of California, San FranciscoRecruiting18 Years64 YearsAll10Phase 1United States
9ChiCTR-IOR-160080472016-03-018 January 2018Early intervention of extracranial arteriovenous malformations with bleomycin: a prospective, multicenter, single-blind, randomized, controlled clinical trialEarly intervention of extracranial arteriovenous malformations with bleomycin: a prospective, multicenter, single-blind, randomized, controlled clinical trialextracranial arteriovenous malformationsbleomycin group:Intralesional Bleomycin Injection;Control group:No medicine;Shanghai 9th People's Hospital, Shanghai Jiaotong University School of MedicineRecruitingBothbleomycin group:80;Control group:40;OtherChina
10NCT03076099January 1, 201616 December 2017Dexmedetomidine on Post-operative Blood Pressure in Bain Arteriovenous Malformation EmbolizationEffects of Dexmedetomidine on Post-operative Blood Pressure in Patients Undergoing Brain Arteriovenous Malformation EmbolizationAnesthesiaDrug: Dexmedetomidine;Other: normal salineNan JiangRecruiting18 Years65 YearsAll30N/AChina
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT02552459September 201524 October 2016Effect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in NeurosurgeryEffect of Dexmedetomidine Combined With Sufentanil for Postoperative Intravenous Analgesia in Neurosurgery: A Randomized Controlled StudyArteriovenous MalformationDrug: Sufentanil;Drug: dexmedetomidine 1;Drug: dexmedetomidine 2;Drug: dexmedetomidine 3First Affiliated Hospital, Sun Yat-Sen UniversityRecruiting18 Years65 YearsBoth120Phase 4China
12NCT02042326September 12, 201420 August 2018Prospective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous MalformationsProspective Evaluation of the Efficacy of Sirolimus (Rapamune®) in the Treatment of Severe Arteriovenous MalformationsArteriovenous MalformationsDrug: SirolimusCentre Hospitalier Universitaire, AmiensRecruiting2 YearsN/AAll50Phase 2Belgium;France
13ChiCTR-OOB-150072582014-03-1018 April 2017Early Intervention of Extracranial Arteriovenous Malformations with intralesional bleomycin injections: A Prospective StudyEarly Intervention of Extracranial Arteriovenous Malformations with intralesional bleomycin injections: A Prospective StudyArteriovenous Malformationbleomycin group:intralesional adminstrated bleomycin ;Shanghai 9th People's Hospital, Shanghai Jiaotong University School of MedicineRecruiting260Bothbleomycin group:30;OtherChina
14NCT02496013January 201416 December 2017Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEBRadiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Diagnostic Performance of 68Ga-NEB in Healthy Volunteers and Patients With Hepatic Space-occupying Lesions and Suspicious Lymph Nodes MetastasisArteriovenous Malformation;Hemangioma;Neoplasms Lymph Nodes;LymphedemaDrug: 68Ga-NEBPeking Union Medical College HospitalNational Institute for Biomedical Imaging and Bioengineering (NIBIB)Recruiting18 YearsN/AAll70Phase 1China
15NCT00783523March 200819 February 2015Influence of MMP on Brain AVM HemorrhageInfluence of Matrix Metalloproteinase on Brain Arteriovenous Malformation HemorrhageArteriovenous Malformations;Cavernous Angiomas;Brain AneurysmsDrug: Doxycycline or PlaceboUniversity of California, San FranciscoNot recruiting13 YearsN/ABoth33Phase 1United States
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
16NCT00389935October 200619 February 2015Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal BleedingThalidomide Reduces Arteriovenous Malformation Related Gastrointestinal BleedingArteriovenous Malformation;Hereditary Hemorrhagic Telangiectasia;Hematochezia;MelenaDrug: ThalidomideNorthport Veterans Affairs Medical CenterGeorgia Regents University;University of Massachusetts, WorcesterNot recruiting18 YearsN/ABoth14Phase 2United States
17NCT00243893July 200419 February 2015Tetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and AneurysmsTetracycline-Derivatives for Treatment of Cerebral Arteriovenous Malformations and AneurysmsAneurysms;Arteriovenous MalformationsDrug: minocycline;Drug: doxycyclineUniversity of California, San FranciscoNational Institute of Neurological Disorders and Stroke (NINDS)Not recruiting13 Years80 YearsBoth26Phase 1United States

先頭へ